Back
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.
Journal article

Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.

  • Nowak-Sliwinska P School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland; Translational Research Center in Oncohaematology, University of Geneva, Rue Michel Servet 1, 1211 Geneva 4, Switzerland. Electronic address: Patrycja.Nowak-Sliwinska@unige.ch.
  • Scapozza L School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland.
  • Ruiz i Altaba A Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Rue Michel Servet 1, 1211 Geneva 4, Switzerland.
  • 2019-04-30
Published in:
  • Biochimica et biophysica acta. Reviews on cancer. - 2019
Colorectal cancer
Computational approaches
Drug repositioning
Mechanism of action
Omics
On/off-target effects
Phenotypes
Polypharmacology
Repurposing in oncology
Side effects
Signaling pathways
Animals
Antineoplastic Agents
Colorectal Neoplasms
Drug Repositioning
Humans
Machine Learning
Medical Oncology
Phenotype
English The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the number of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient. The key question we address is how to efficiently repurpose an existing drug to treat a given indication. As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chemical genetics and omics assays to successfully predict disease-drug pairs. Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments. Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates. We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/232842
Statistics
Document views: 9 File downloads: